AEROCRINE AB RECEIVES US FDA MARKET CLEARANCE FOR NIOX VERO®

SOLNA, Sweden - Aerocrine AB (OMX Nordic Exchange: AERO) receives US FDA market
clearance for the company’s next generation device, NIOX VERO®.  Launch planned
for Q1 2015.
Aerocrine received notification that the United States Food and Drug
Administration (FDA) has granted market clearance for NIOX VERO, the company’s
next generation device for measuring Fractional exhaled Nitric Oxide (FeNO)
levels in the clinical setting.

“The portability and patient-centered improvements provided by NIOX VERO will
make it more practical for specialists as well as primary care physicians to
make FeNO testing a routine part of identifying and managing allergic airway
inflammation in patients with diagnosed or suspected asthma,” said Scott Myers,
CEO of Aerocrine, AB.

NIOX VERO is a small, point-of-care device that provides a patient’s FeNO score
in about 1 minute after a simple 10-second exhalation. The device improves on
the previous generation NIOX MINO® by including a rechargeable battery for
portability within the clinical setting and an integrated visual display to help
patients complete a successful exhalation. Aerocrine’s NIOX MINO and now NIOX
VERO are the only FeNO measurement devices cleared by the FDA and commercially
available in the United States.

“FeNO testing is an important addition to clinicians’ tool set because it is the
only way to objectively identify and manage allergic airway inflammation, which
is the leading cause of asthma symptoms,” said Dr. Kathleen Rickard, Chief
Medical Officer at Aerocrine. “Routine FeNO testing helps clinicians find hidden
and under-treated allergic airway inflammation, which has been shown to help
reduce asthma exacerbations by up to 50 percent compared to usual care.”

Asthma is one of the most common diseases in the United States, affecting 8-10%
of the population and accounting for an estimated 90 million patient
interactions with healthcare providers each year. Over half of those patient
interactions are with adult and pediatric primary care practitioners. The
disease has no cure and proper diagnosis and management of the disease are key
to obtaining optimal control of a patient’s asthma.

For more information about Aerocrine:

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336

Dr. Kathleen Rickard, Chief Medical Officer, Aerocrine AB: +1 919 749 6708

Marshall Woodworth, Chief Financial Officer, Aerocrine AB: +1 919 749 8748 or
+46 709 695 219

Or visit www.aerocrine.com

About Aerocrine

Aerocrine AB is a medical products company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in technology to monitor and manage airway inflammation, Aerocrine
markets NIOX MINO® and NIOX VERO®. Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on
the Stockholm Stock Exchange in 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 5:00 p.m. on November 6, 2014.